Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$190.91 -0.1%	$184.21	$163.52 ▼ $218.66	$337.22B	0.5	6.24 million shs	4.20 million shs
BMY Bristol-Myers Squibb	$48.65 -2.2%	$48.71	$39.35 ▼ $63.33	$99.01B	0.38	13.00 million shs	14.97 million shs
MRK Merck & Co., Inc.	$80.97 -0.9%	$78.93	$73.31 ▼ $134.63	$203.31B	0.38	12.87 million shs	12.57 million shs
PFE Pfizer	$24.40 -0.6%	$23.06	$20.92 ▼ $31.54	$138.71B	0.57	41.18 million shs	35.08 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	+0.41%	+3.61%	-11.09%	+13.10%
BMY Bristol-Myers Squibb	0.00%	+2.65%	+6.28%	-17.25%	+20.64%
MRK Merck & Co., Inc.	0.00%	+3.45%	+7.36%	-13.88%	-36.92%
PFE Pfizer	0.00%	+4.93%	+7.39%	-5.97%	-10.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9012 of 5 stars	3.4	5.0	3.3	3.9	3.0	2.5	1.3
BMY Bristol-Myers Squibb	4.8103 of 5 stars	3.2	5.0	4.2	4.0	2.9	3.3	0.0
MRK Merck & Co., Inc.	4.9964 of 5 stars	3.2	5.0	5.0	3.9	2.9	2.5	3.8
PFE Pfizer	4.9768 of 5 stars	3.3	4.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	10.67% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$58.00	19.22% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	34.86% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	19.55% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRK, ABBV, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/25/2025	BMY Bristol-Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$57.37B	5.88	$14.11 per share	13.53	$1.90 per share	100.48
BMY Bristol-Myers Squibb	$47.64B	2.08	$5.13 per share	9.48	$8.08 per share	6.02
MRK Merck & Co., Inc.	$63.92B	3.18	$2.81 per share	28.82	$14.85 per share	5.45
PFE Pfizer	$62.46B	2.22	$3.82 per share	6.38	$15.81 per share	1.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	79.55	13.66	1.62	7.59%	296.28%	12.65%	7/24/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	$2.67	N/A	7.99	2.07	-18.53%	13.93%	2.46%	7/31/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	12.03	8.18	0.77	26.67%	45.35%	17.36%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.30	8.05	0.64	12.62%	19.47%	8.09%	7/29/2025 (Estimated)

Latest PFE, MRK, ABBV, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.44%	N/A	279.15%	53 Years
BMY Bristol-Myers Squibb	$2.48	5.10%	N/A	92.88%	17 Years
MRK Merck & Co., Inc.	$3.24	4.00%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	7.05%	N/A	124.64%	16 Years

Latest PFE, MRK, ABBV, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
BMY Bristol-Myers Squibb	2.90	1.25	1.15
MRK Merck & Co., Inc.	0.79	1.36	1.15
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol-Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol-Myers Squibb	0.09%
MRK Merck & Co., Inc.	0.13%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
BMY Bristol-Myers Squibb	34,300	2.04 billion	2.03 billion	Optionable
MRK Merck & Co., Inc.	69,000	2.51 billion	2.53 billion	Optionable
PFE Pfizer	83,000	5.69 billion	5.66 billion	Optionable

PFE, MRK, ABBV, and BMY Headlines

Recent News About These Companies

Pfizer (PFE) Experiences Mixed Options Sentiment Amidst Price Drop | PFE Stock News

June 16 at 2:17 PM | gurufocus.com

PFE or LLY: Which Is the Better Value Stock Right Now?

June 16 at 12:41 PM | zacks.com

4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil

June 16 at 10:31 AM | zacks.com

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

June 16 at 10:11 AM | zacks.com

Signature Wealth Management Group Purchases 20,873 Shares of Pfizer Inc. (NYSE:PFE)

June 16 at 7:52 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Stockman Wealth Management Inc.

June 16 at 7:51 AM | marketbeat.com

Claris Advisors LLC MO Purchases 14,647 Shares of Pfizer Inc. (NYSE:PFE)

June 16 at 7:51 AM | marketbeat.com

QRG Capital Management Inc. Has $17.74 Million Position in Pfizer Inc. (NYSE:PFE)

June 16 at 7:44 AM | marketbeat.com

Hanson & Doremus Investment Management Raises Position in Pfizer Inc. (NYSE:PFE)

June 16 at 6:08 AM | marketbeat.com

Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT

June 15 at 4:48 PM | msn.com

Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

June 15 at 4:48 PM | finance.yahoo.com

Trust Co. of Toledo NA OH Grows Holdings in Pfizer Inc. (NYSE:PFE)

June 15 at 9:03 AM | marketbeat.com

Mn Services Vermogensbeheer B.V. Has $52.41 Million Position in Pfizer Inc. (NYSE:PFE)

June 15 at 9:02 AM | marketbeat.com

Exchange Traded Concepts LLC Purchases 516,582 Shares of Pfizer Inc. (NYSE:PFE)

June 15 at 7:59 AM | marketbeat.com

Factory Mutual Insurance Co. Cuts Position in Pfizer Inc. (NYSE:PFE)

June 15 at 7:51 AM | marketbeat.com

Atlas Private Wealth Advisors Trims Holdings in Pfizer Inc. (NYSE:PFE)

June 15 at 7:44 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Increased by BayBridge Capital Group LLC

June 15 at 7:43 AM | marketbeat.com

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Has $52.55 Million Stock Position in Pfizer Inc. (NYSE:PFE)

June 15 at 7:21 AM | marketbeat.com

Sound Income Strategies LLC Has $20.04 Million Stake in Pfizer Inc. (NYSE:PFE)

June 15 at 7:21 AM | marketbeat.com

Foster Victor Wealth Advisors LLC Buys 34,440 Shares of Pfizer Inc. (NYSE:PFE)

June 15 at 7:05 AM | marketbeat.com

Wilsey Asset Management Inc. Acquires 58,372 Shares of Pfizer Inc. (NYSE:PFE)

June 15 at 6:16 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
By Jeffrey Neal Johnson | May 23, 2025
View Pfizer's 7.5% Dividend: Income Haven or House of Cards?

PFE, MRK, ABBV, and BMY Company Descriptions

AbbVie NYSE:ABBV

$190.91 -0.17 (-0.09%)

Closing price 03:59 PM Eastern

Extended Trading

$190.28 -0.63 (-0.33%)

As of 08:00 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol-Myers Squibb NYSE:BMY

$48.65 -1.10 (-2.21%)

Closing price 03:59 PM Eastern

Extended Trading

$48.72 +0.07 (+0.15%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$80.96 -0.75 (-0.91%)

Closing price 03:59 PM Eastern

Extended Trading

$80.64 -0.32 (-0.40%)

As of 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.40 -0.14 (-0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$24.38 -0.02 (-0.07%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time